Physician profile
Christopher Anson Henry
NPI 1225263684
$6,452.67
in general payments reported to CMS, 2019-2025
24 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $256 · 2021: $357 · 2022: $1,173 · 2023: $951 · 2024: $2,394 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Travel and Lodging: $1,536 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.22 |
| Travel and Lodging | $1,535.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,815.60 | 2020-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $728.34 | 2019-2024 | Lithovue |
| Olympus America INC. | $282.22 | 2019-2025 | Itind System |
| Astellas Pharma US INC | $198.22 | 2023-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $180.11 | 2024-2025 | Gemtesa |
| Calyxo, INC. | $152.67 | 2025 | Cvac Aspiration System |
| Pfizer INC. | $137.61 | 2019-2024 | |
| Procept Biorobotics Corporation | $107.14 | 2025 | |
| 180 Medical, INC. | $106.91 | 2023-2025 | Gentlecath, Cure Ultra Catheter |
| Endo Pharmaceuticals INC. | $102.17 | 2022-2024 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $86.15 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $72.27 | 2022-2025 | |
| Endo USA, INC. | $70.23 | 2025 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $70.04 | 2023-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $52.13 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $51.36 | 2024 | |
| Tolmar, INC. | $47.56 | 2024 | |
| Myriad Genetic Laboratories, INC. | $46.46 | 2024-2025 | Myrisk |
| C. R. Bard, INC. & Subsidiaries | $37.70 | 2024 | Bard Urinary Drainage Bag |
| Ethicon US, LLC | $29.48 | 2019 | |
| Teleflex LLC | $24.02 | 2024 | Urolift |
| Takeda Pharmaceuticals U.S.A., INC. | $18.95 | 2025 | Eohilia |
| Halozyme INC | $18.81 | 2023 | |
| Allergan, INC. | $16.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.